Sumac Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.20 M
as on 08-07-2024
- Paid Up Capital ₹ 1.20 M
as on 08-07-2024
- Company Age 32 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 6.30 M
as on 08-07-2024
- Revenue -1.72%
(FY 2020)
- Profit -458.03%
(FY 2020)
- Ebitda -295.52%
(FY 2020)
- Net Worth -27.84%
(FY 2020)
- Total Assets 0.98%
(FY 2020)
About Sumac Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.20 M and a paid-up capital of Rs 1.20 M.
The company has closed loans amounting to ₹6.30 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Suryamanikyam Manepalli and Naga Murthy serve as directors at the Company.
- CIN/LLPIN
U24239TG1992PTC013813
- Company No.
013813
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Feb 1992
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Sumac Pharma Private Limited offer?
Sumac Pharma Private Limited offers a wide range of products and services, including Women Care, Mother Care.
Who are the key members and board of directors at Sumac Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Naga Murthy  | Managing Director | 24-Oct-2012 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Suryamanikyam Manepalli | Director | 20-Nov-2017 | Current |
Financial Performance of Sumac Pharma.
Sumac Pharma Private Limited, for the financial year ended 2020, experienced Minor drop in revenue, with a 1.72% decrease. The company also saw a substantial fall in profitability, with a 458.03% decrease in profit. The company's net worth observed a substantial decline by a decrease of 27.84%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sumac Pharma?
In 2019, Sumac Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
A.P.S.F.C. Creation Date: 02 Feb 1996 | ₹0.48 M | Satisfied |
Andhra Bank Creation Date: 10 Feb 1993 | ₹4.00 M | Satisfied |
A.P. State Finanical Corporation Creation Date: 20 Oct 1992 | ₹1.82 M | Satisfied |
How Many Employees Work at Sumac Pharma?
Sumac Pharma has a workforce of 21 employees as of Mar 22, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sumac Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sumac Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
